Thanks for posting this article. Tom Roth, a long standing clinician in sleep studies, has a very good perspective here, IMHO.
There is one incorrect statement by the author of the article, however.
Ambien and Lunesta, the current best-selling insomnia medications according to data compiled by Bloomberg, essentially subdue GABA receptors, which are spread throughout the central nervous system, putting people to sleep and acting as a muscle relaxant, anxiety reducer and anti-convulsant.
The current GABAergic drugs DO NOT subdue GABA receptors, they activate them. GABA-A receptors are inhibitory receptors and ~75-90% of neurotransmission is inhibitory in the CNS, mediated primarily by GABA-A receptors.
My view is that suvorexant will be a non-scheduled drug.